<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Clozapine-Induced Locomotor Suppression is Mediated by 5-HT2A Receptors in the Forebrain</title>
				<funder>
					<orgName type="full">NH&amp;MRC (CEM)</orgName>
				</funder>
				<funder>
					<orgName type="full">NIMH</orgName>
				</funder>
				<funder ref="#_aN33awG">
					<orgName type="full">NIDA</orgName>
				</funder>
				<funder>
					<orgName type="full">Acadia Pharmaceuticals</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher>Springer Science and Business Media LLC</publisher>
				<availability status="unknown"><p>Copyright Springer Science and Business Media LLC</p>
				</availability>
				<date type="published" when="2012-08-08">8 August 2012</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Caitlin</forename><forename type="middle">E</forename><surname>Mcomish</surname></persName>
							<email>caitlin.mcomish@gmail.com</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">Columbia University Medical Center</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Florey Neurosciences Institute</orgName>
								<address>
									<addrLine>Melbourne VIC</addrLine>
									<settlement>Parkville</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">University of Melbourne</orgName>
								<address>
									<addrLine>Melbourne VIC</addrLine>
									<settlement>Parkville</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alena</forename><surname>Lira</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">Columbia University Medical Center</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">James</forename><forename type="middle">B</forename><surname>Hanks</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Mount Sinai School of Medicine</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jay</forename><forename type="middle">A</forename><surname>Gingrich</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">Columbia University Medical Center</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Sackler Institute</orgName>
								<orgName type="institution">New York State Psychiatric Institute</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">Columbia University Medical Center</orgName>
								<address>
									<addrLine>1051 Riverside Drive</addrLine>
									<postCode>10032</postCode>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Clozapine-Induced Locomotor Suppression is Mediated by 5-HT2A Receptors in the Forebrain</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Neuropsychopharmacology</title>
						<title level="j" type="abbrev">Neuropsychopharmacol</title>
						<idno type="ISSN">0893-133X</idno>
						<idno type="eISSN">1740-634X</idno>
						<imprint>
							<publisher>Springer Science and Business Media LLC</publisher>
							<biblScope unit="volume">37</biblScope>
							<biblScope unit="issue">13</biblScope>
							<biblScope unit="page" from="2747" to="2755"/>
							<date type="published" when="2012-08-08">8 August 2012</date>
						</imprint>
					</monogr>
					<idno type="MD5">CC327080F1898D3441878820F2C6F2C9</idno>
					<idno type="DOI">10.1038/npp.2012.139</idno>
					<note type="submission">Received 9 April 2012; revised 11 June 2012; accepted 29 June 2012</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2025-04-21T20:04+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>5-HT 2A receptor</term>
					<term>clozapine</term>
					<term>schizophrenia</term>
					<term>side effects</term>
					<term>antipsychotics</term>
					<term>sedation</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The need for safer, more effective therapeutics for the treatment of schizophrenia is widely acknowledged.</s><s>To optimally target novel pharmacotherapies, in addition to establishing the mechanisms responsible for the beneficial effects of antipsychotics, the pathways underlying the most severe side effects must also be elucidated.</s><s>Here we investigate the role of serotonin 2A (5-HT 2A ), serotonin 2C (5-HT 2C ), and dopamine 2 receptors (D 2 ) in mediating adverse effects associated with canonical first-and second-generation antipsychotic drugs in mice.</s><s>Wild-type (WT) and 5-HT 2A knockout (KO) mice treated with haloperidol, clozapine, and risperidone were assessed for locomotor activity and catalepsy.</s><s>WT mice showed a marked reduction in locomotor activity following acute administration of haloperidol and high-dose risperidone, which was most likely secondary to the severe catalepsy caused by these compounds.</s><s>Clozapine also dramatically reduced locomotor activity, but in the absence of catalepsy.</s><s>Interestingly, 5-HT 2A KO mice were cataleptic following haloperidol and risperidone, but did not respond to clozapine's locomotor-suppressing effects.</s><s>Restoration of 5-HT 2A expression to cortical glutamatergic neurons re-instated the locomotor-suppressing effects of clozapine in the open field.</s><s>In sum, we confirm that haloperidol and risperidone caused catalepsy in rodents, driven by strong antagonism of D 2 .</s><s>We also demonstrate that clozapine decreases locomotor activity in a 5-HT 2A -dependent manner, in the absence of catalepsy.</s><s>Moreover, we show that it is the cortical population of 5-HT 2A that mediate the locomotor-suppressing effects of clozapine.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Schizophrenia is characterized by profound disruptions in thinking, affect, language, perception, and sense of self.</s><s>This impacts upon normal functioning through impaired capacity to earn a livelihood, and while some patients respond well to currently available antipsychotic drugs, others remain symptomatic.</s><s>Findings from the CATIE study <ref type="bibr" target="#b19">(Lieberman et al, 2005)</ref> revealed that up to 74% of patients prescribed atypical antipsychotics discontinued treatment as a result of either ineffectiveness of the antipsychotic or intolerability of the side effects, which include sedation, cardiometabolic risks, extrapyramidal symptoms (EPS), agranulocytosis, and cognitive dulling <ref type="bibr" target="#b18">(Leucht et al, 2009)</ref>.</s></p><p><s>ClozapineFthe prototypical atypical antipsychoticF remains one of the most efficacious antipsychotics available <ref type="bibr" target="#b22">(McEvoy et al, 2006;</ref><ref type="bibr" target="#b24">Meltzer et al, 2003)</ref>.</s><s>Clozapine has been shown to bind upwards of 50 receptor targets in vitro <ref type="bibr" target="#b29">(Roth et al, 2004)</ref> showing strong affinity for dopaminergic, serotonergic, muscarinic, adrenergic, and histaminergic receptors; however, the full spectrum of its in vivo receptor affinity is subject to some discussion <ref type="bibr" target="#b1">(Beninger et al, 2010;</ref><ref type="bibr" target="#b5">Coward, 1992;</ref><ref type="bibr" target="#b21">McCormick et al, 2010;</ref><ref type="bibr" target="#b29">Roth et al, 2004;</ref><ref type="bibr" target="#b32">Schotte et al, 1993)</ref>.</s><s>Although it pioneered second-generation drugs, which have lower liability to cause EPS and tardive dyskinesias, these compounds are hampered by side effects such as weight gain, hyperlipidemia, agranulocytosis, and sedation.</s><s>The severity of these side effects is such that clozapine is prescribed for treatment only as a last resort.</s><s>A better understanding of how clozapine and other atypical antipsychotics produce both therapeutic and unwanted effects remains a field of active investigation.</s></p><p><s>The most popular explanation for the improved efficacy in treating negative symptoms and the low EPS produced by atypical antipsychotic compounds is the addition of strong serotonin 2A receptor (5-HT 2A ) antagonism.</s><s>Antagonism of 5-HT 2A in mesocortical pathways is hypothesized to be one of the mechanisms underlying the improvement of negative symptoms produced by atypical antipsychotics, whereas the attenuated EPS have been proposed to be the result of 5-HT 2A antagonist-driven dopamine release in the striatum <ref type="bibr" target="#b23">(Meltzer and Massey, 2011)</ref>.</s><s>However, studies investigating these hypotheses have provided mixed results in both humans and mice, and alternative hypotheses have been proposed to explain the reduction in EPS, including an anti-cholinergic mechanism or the action of a2-adrenoceptor antagonism <ref type="bibr">(Kalkman et al, 1998a, b;</ref><ref type="bibr" target="#b27">Parada et al, 1997)</ref>.</s></p><p><s>To shed light upon the manner by which atypical antipsychotics circumvent the induction of EPS, we used a combined pharmacological and genetic strategy.</s><s>If the prevailing hypotheses held true, then administering haloperidol either in combination with a 5-HT 2A antagonist or to a 5-HT 2A knockout mouse (KO) should shift the phenotype from catalepsy/EPS to something more closely resembling the effects of atypical antipsychotics.</s><s>Moreover, using a STOP-floxed 5-HT 2A transgenic mouse, we should be able to pinpoint the neural loci controlling this behavioral shift.</s></p><p><s>Contrary to our hypothesis, we found that 5-HT 2A signaling alone does not appear to be critical to the shift away from EPS in second-generation drugs.</s><s>Interestingly, we found that the receptor plays a key role in the regulation of locomotor suppression produced by atypical antipsychotics, like clozapine, and that this response relied upon the expression of 5-HT 2A specifically in the forebrain.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animals</head><p><s>Animals were housed on a 12 h light/dark cycle with food and water available ad libitum.</s><s>All testing was carried out during the light cycle on 5-HT 2A KO mice and wild-type (WT) littermate controls on a 129SvEv/Tac background originally obtained from Taconic (Taconic Farms).</s><s>Mice heterozygous for a transgenic STOP cassette flanked by LoxP sites located upstream of the htr2a gene <ref type="bibr" target="#b41">(Weisstaub et al, 2006)</ref> were crossed, generating WT, KO, and heterozygous littermates, identified by PCR genotyping.</s><s>Mice were weaned at 3-4 weeks of age and behavioral testing began at 12 weeks.</s></p><p><s>Restricted expression of specific populations of 5-HT 2A was achieved as described previously.</s><s>Briefly, STOP-floxed htr2a transgenic mice were crossed with mice expressing Emx1-Cre to selectively express 5-HT 2A in Emx1-positive cells (predominantly pyramidal forebrain neurons as has been demonstrated previously; <ref type="bibr" target="#b41">Weisstaub et al, 2006)</ref>.</s><s>A DAT-Cre mouse line was used to selectively restore 5-HT 2A expression to DAT-containing nigrostriatal neurons.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Drugs</head><p><s>Antipsychotics were tested at a range of doses (Figure <ref type="figure" target="#fig_0">1</ref>) before selecting a single dose for subsequent testing: clozapine (5 mg/kg), haloperidol (0.4 mg/kg), risperidone (0.4 mg/kg), AC90179 (10 mg/kg), which shows high potency as an inverse agonist and a competitive antagonist at the 5-HT 2A , and SB242084 (1 mg/kg), a 5-HT 2C inverse agonist with some activity at the 5-HT 2B receptor or vehicle (1% Tween-80 at pH 6.0).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Locomotor Activity</head><p><s>Animals were treated intraperitoneally 30 min before being placed in the MedAssociates locomotor arena, and were then tracked for 30 min using the MedAssociates software.</s><s>Diphenhydramine displayed a shorter window of efficacy on behavior.</s><s>As a result, mice were placed in the locomotor arena immediately following drug administration.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Catalepsy Assessment</head><p><s>Catalepsy was assessed using the step down task.</s></p><p><s>Step down task was performed by placing the forepaws or hindpaws on a bar 0.8 cm in diameter fixed at 3.5 cm from the bench top.</s><s>Haloperidol, at doses of 0.1 mg/kg and higher, significantly decreased locomotor activity in both wild-type (WT) and serotonin 2A (5-HT 2A ) knockout (KO) mice (a: untreated, N ¼ 26 WT, 34 KO; haloperidol treated, N ¼ 11 KO, 9 WT).</s><s>Risperidone at both low and high doses also decreased activity comparably in both WT and KO mice (b: untreated, N ¼ 26 WT, 34 KO; haloperidol treated, N ¼ 11 KO, 9 WT).</s><s>Clozapine treatment resulted in extreme sedation in WT mice from 5 mk/kg upwards (c: untreated, N ¼ 26 WT, 34 KO; haloperidol treated, N ¼ 12 KO, 8 WT).</s><s>In KO mice, clozapine did not induce this extreme level of sedation until 30 mg/kg.</s><s>Data are shown as mean±SEM.</s><s># Po0.05 difference from WT.</s></p><p><s>Mice were injected intraperitoneally 30 min before testing.</s><s>Time to step down was measured for three consecutive trials for an average step down time.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neurological Reflex/Motor Behavior</head><p><s>Righting reflex was assessed using a subjective scoring matrix.</s><s>A score of 0 was allocated to mice that righted immediately (too quickly to time accurately), 1 for animals that turned noticeably more slowly (righted in approximately 1 s), a score of 2 was given to animals that displayed great difficulty in turning over (righted in 1 + s), and a score of 3 indicated mice that did not right at all.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose Response to Haloperidol, Risperidone, and Clozapine</head><p><s>Clozapine, haloperidol, and risperidone display distinct pharmacology.</s><s>Haloperidol, a typical antipsychotic, demonstrates highest affinity for the D 2 receptor and s 1 receptor, robustly antagonizing signaling at relatively low doses <ref type="bibr" target="#b29">(Roth et al, 2004;</ref><ref type="bibr" target="#b31">Schotte et al, 1996)</ref>.</s><s>Risperidone possesses a broader spectrum, showing high in vitro affinity for 5-HT 2A , 5-HT 7 , D 2 , a 1 , and H 1 , and is reported to act like an atypical antipsychotic at lower doses, but more like a typical antipsychotic at higher doses <ref type="bibr" target="#b29">(Roth et al, 2004;</ref><ref type="bibr" target="#b31">Schotte et al, 1996)</ref>.</s><s>Clozapine has a complex pharmacology, binding to upwards of 50 receptors with demonstrable affinity for 5-HT 2A , 5-HT 2C , D 2 , H 1 , and M 1 receptors <ref type="bibr" target="#b29">(Roth et al, 2004;</ref><ref type="bibr" target="#b31">Schotte et al, 1996;</ref><ref type="bibr" target="#b44">Yadav et al, 2011)</ref>.</s></p><p><s>Haloperidol dramatically reduced activity across both genotypes (Figure <ref type="figure" target="#fig_0">1a</ref>: effect of treatment, F (7, 224) ¼ 28.706, Po0.0001; effect of genotype, F (1, 224) ¼ 0.465, P ¼ 0.4958; genotype Â treatment interaction, F (7, 224) ¼ 0.338, P ¼ 0.9359).</s><s>A significant effect of genotype was detected in the risperidone dose-response curve in addition to the treatment effect; however, the genotypes were not differentially affected by the treatment (Figure <ref type="figure" target="#fig_0">1b</ref>: effect of treatment, F (7, 224) ¼ 21.972, Po0.0001; effect of genotype, F (1, 224) ¼ 4.065, Po0.05; genotype Â treatment interaction, F (7, 224) ¼ 0.084, P ¼ 0.9990).</s><s>Clozapine affected WT and 5-HT 2A KO mice differentially (Figure <ref type="figure" target="#fig_0">1c</ref>: effect of treatment, F (7, 224) ¼ 13.169, Po0.0001; effect of genotype, F (1, 224) ¼ 22.166, Po0.0001; genotype Â treatment interaction, F (7, 224) ¼ 2.698, Po0.05): decreasing mice locomotor activity in WT mice in a dose dependent manner.</s><s>5-HT 2A KO displayed a U-shaped dose-response curve, which may be attributable to the increased 5-HT 2C antagonism at higher doses of clozapine.</s></p><p><s>From these dose-response curves, a dose of 5 mg/kg was chosen for clozapine, 0.4 mg/kg for haloperidol, and 0.4 mg/kg for risperidone.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antipsychotic-Induced Catalepsy Occurs Independently of 5HT 2A Receptors</head><p><s>Typical antipsychotics provoke a cataleptic response in mice, which is considered to be analogous to EPS in human patients.</s><s>This response is widely attributed to the robust antagonism of D 2 receptors in both mice and humans; however, it has also been suggested to be susceptible to modulation by 5-HT 2A .</s></p><p><s>No significant effect of 5-HT 2A genotype was observed in the dose-response analysis of catalepsy (Figure <ref type="figure" target="#fig_1">2a</ref>: haloper-idolFeffect of treatment, F (7, 704) ¼ 235.118,</s><s>Po0.0001; effect of genotype, F (1, 2.513) ¼ 0.465, P ¼ 0.1134; risperidone Feffect of treatment, F (7, 704) ¼ 169.293,</s><s>Po0.0001; effect of genotype, F (1, 704) ¼ 0.001, P ¼ 0.9737).</s></p><p><s>With the selected doses of antipsychotics, a significant statistical effect of treatment was observed in response to antipsychotic drugs (Figure <ref type="figure" target="#fig_1">2b</ref>: ANOVA effect of genotype, F (1, 260) ¼ 0.338, P ¼ 0.5614; effect of treatment, F (3, 260) ¼ 102.44,</s><s>Po0.0001).</s><s>Haloperidol and risperidone induced catalepsy on the step down task (Figure <ref type="figure" target="#fig_1">2b</ref>: haloperidol compared with vehicle-treated animals, Po0.0001; risperidone vs vehicle, Po0.0001).</s><s>Clozapine did not cause catalepsy in mice (P ¼ 0.4815) nor did the administration of AC90179 (Figure <ref type="figure" target="#fig_1">2c</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>5HT 2A KO Mice Show Altered Locomotor Response to Clozapine, but not Risperidone or Haloperidol</head><p><s>Antipsychotic treatment significantly reduced locomotor activity (Figure <ref type="figure">3a</ref>: effect of treatment, F (3, 71) ¼ 10.841, Po0.0001).</s><s>There was also a significant overall effect of 5-HT 2A genotype (F (1, 71) ¼ 12.231, Po0.001) and an interaction (F (3, 71) ¼ 10.841, Po0.001).</s><s>Post hoc analyses revealed that in WT mice, haloperidol (Po0.0001),</s><s>risperidone (Po0.0001), and clozapine (Po0.01)</s><s>all caused significant reduction of locomotor activity (Figure <ref type="figure">3a</ref>).</s></p><p><s>Haloperidol and risperidone decreased activity equally in both WT and 5-HT 2A KO mice.</s><s>This is most likely a corollary of the catalepsy induced by these drugs at the doses used.</s><s>Clozapine, in the absence of catalepsylike behavior, showed a gene Â treatment interaction (F (1, 35) ¼ 8.386, Po0.01): 5-HT 2A KO mice were resistant to the locomotor suppression produced by clozapine (Figure <ref type="figure">3a</ref>: Po0.01 compared to WT mice).</s></p><p><s>The 5-HT 2C receptor antagonist SB242084 significantly increased locomotor activity (Figure <ref type="figure">3b</ref>: effect of treatment, F (3, 78) ¼ 18.865, Po0.0001; effect of genotype, F (1, 78) ¼ 9.865, Po0.01; SB242084 vs vehicle, Po0.0001; AC90179 vs vehicle, P ¼ 0.7613).</s><s>In 5-HT 2A KO mice, coadministration of AC90179 and SB242084 produced the same increased activity observed following SB242084 alone (Po0.05).</s><s>In WT mice, the combined antagonism of the 5-HT 2A and 5-HT 2C resulted no significant differences from vehicle-treated mice (P ¼ 0.4052) indicative of a counterbalancing effect of 5-HT 2A and 5-HT 2C antagonism on locomotor activity.</s></p><p><s>Combined D 2 and 5-HT 2A antagonism caused significant locomotor suppression, independent of genotype, an effect that was similar to that of haloperidol alone (Figure <ref type="figure">3c</ref>: effect of treatment, F (3, 75) ¼ 39.284, Po0.0001; effect of genotype, F (1, 75) ¼ 1.898, P ¼ 0.1724; haloperidol + AC90179 vs haloperidol, P ¼ 0.9647; haloperidol + AC90179 vs risperidone, P ¼ 0.8570), and was significantly different to vehicle treatment (Po0.0001).</s><s>Interestingly, SB242084 administered in combination with haloperidol resulted in a significant reduction in locomotor activity compared to SB242084 alone (Figure <ref type="figure">3d</ref>: effect of treatment, F (3, 78) ¼ 17.584, Po0.0001; effect of genotype, F (1, 78) ¼ 0.145, P ¼ 0.7042; haloperidol + SB242084 vs SB242084, Po0.001), but not significantly different from vehicle (P ¼ 0.6860) nor haloperidol alone (P ¼ 0.1103; Figure <ref type="figure">3d</ref>).</s></p><p><s>The genotype effect of clozapine administration could be recapitulated by treating mice with risperidone (which shares clozapine's affinity at the D 2 and 5-HT 2A ) in combination with SB242084 (Figure <ref type="figure">3e</ref>: effect of treatment, F (3, 74) ¼ 2.002, P ¼ 0.121; effect of genotype, F (1, 74) ¼ 7.569, Po0.01; treatment Â genotype interaction, F (3,74) ¼ 1.473, P ¼ 0.2288).</s><s>WT mice display locomotor suppression comparable to clozapine alone (risperidone + SB242084 vs clozapine, P ¼ 0.8255), which was significantly different from their baseline activity (Po0.01),</s><s>whereas 5-HT 2A KO mice, following risperidone and SB242084, were not different from vehicle treatment (P ¼ 0.7472) or clozapine treatment (P ¼ 0.3536).</s><s>This was also achievable by the combination of haloperidol, AC90179, and SB242084, which in WT mice was significantly different from vehicle treatment (Po0.05), but not clozapine treatment (P ¼ 0.3290), while in 5-HT 2A KO mice there was no difference between this combination of drugs and vehicle (P ¼ 0.6210), or clozapine (P ¼ 0.8972).</s></p><p><s>Thus, clozapine suppresses locomotor activity in a 5-HT 2A -dependent manner, in the absence of catalepsy, suggesting an alternate mechanism.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Differential Response to Atypical Antipsychotics in 5-HT 2A KO Mice is not due to Changes in Histaminergic or Muscarinic Signaling</head><p><s>To determine the involvement of 5-HT 2C in mediating locomotor suppression induced by clozapine, 5-HT 2C knockout mice were treated with either saline or clozapine and assessed in the open field.</s><s>WT and 5-HT 2C KO mice displayed comparable levels of locomotor suppression following 5 mg/kg clozapine treatment (Figure <ref type="figure" target="#fig_3">4a</ref>: treatment effect, F (1, 29) ¼ 15.146, Po0.001; genotype effect, F (1, 29) ¼ 0.003, P ¼ 0.9564).</s></p><p><s>Moreover the behavioral response to clozapine was found to generalize to other, similar atypical antipsychotics.</s><s>Olanzapine dramatically reduced locomotion (Figure <ref type="figure" target="#fig_3">4b</ref>: effect of treatment, F (1, 33) ¼ 12.671, Po0.01; effect of genotype, F (1, 33) ¼ 2.031, P ¼ 0.1635; genotype Â treatment interaction, F (1, 33) ¼ 4.979, Po0.05), an effect that was again observed to be muted in 5-HT 2A KO mice (Po0.0001).</s></p><p><s>Given clozapine's affinity for M1 and H1, and the possible interactions between these receptors and the 5-HT 2A <ref type="bibr" target="#b12">(Hirano et al, 1995;</ref><ref type="bibr" target="#b25">Morisset et al, 1999)</ref>, locomotor response to muscarinic and histaminergic antagonism were assessed to test the hypothesis that the differential response to atypical antipsychotics may be a product of alterations in these neurotransmitter systems.</s><s>Mice showed robust locomotor activation following scopolamine treatment (1 mg/kg) independent of their genotype (Figure <ref type="figure" target="#fig_3">4c</ref>: effect of treatment, F (1, 36) ¼ 73.721, Po0.0001; effect of genotype, F (1, 36) ¼ 0.290, P ¼ 0.5937).</s><s>Diphenhydramine (6 mg/kg) also increased locomotor activity equally in both WT and 5-HT 2A KO mice (effect of treatment, F (1, 36) ¼ 8.899, Po0.01; effect of genotype, F (1, 36) ¼ 0.011, P ¼ 0.9176).</s></p><p><s>Forebrain Glutamatergic 5HT 2A is Sufficient to Recapitulate the WT-Like Response to Atypical Antipsychotics Transgenic animals with 5-HT 2A selectively expressed in restricted neural regions were generated as described previously <ref type="bibr" target="#b41">(Weisstaub et al, 2006)</ref>.</s><s>The Emx1 lineage of cells includes cortical and hippocampal glutamatergic neurons in addition to subpopulations of oligodendrocytes and astrocytes <ref type="bibr" target="#b9">(Gorski et al, 2002;</ref><ref type="bibr" target="#b10">Guo et al, 2000)</ref>, whereas the DAT-Cre results in strong recombination in the VTA and SNc, in addition to weak expression in the olfactory bulb and the hypothalamus <ref type="bibr" target="#b45">(Zhuang et al, 2005)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Locomotor activity.</head><p><s>Emx1-Cre: As observed previously, we found an overall effect of genotype (F (3, 50) ¼ 4.233, Po0.01; Figure <ref type="figure" target="#fig_4">5a</ref>) and treatment (F (1, 50) ¼ 28.888, Po0.0001), as well as an interaction (F (3, 50) ¼ 3.125, Po0.05).</s><s>Clozapine severely reduced locomotor activity relative to saline treatment in WT and Cre control animals (Po0.01 for WT and Po0.001 for Cre control; Figure <ref type="figure" target="#fig_4">5a</ref>).</s><s>5-HT 2A KO mice were not susceptible to the locomotor-suppressing effects of clozapine, showing no significant differences compared with their KO saline-treated littermates (P ¼ 0.9503).</s><s>5-HT 2A expression in forebrain glutamatergic neurons alone was sufficient to restore the locomotor-suppressing effects of clozapine (Po0.01; Figure <ref type="figure" target="#fig_4">5a</ref>).</s></p><p><s>DAT-Cre: Given the important role of dopamine in motor behavior and the high expression of 5-HT 2A on dopamine neurons, we had hypothesized that antagonism of this population of 5-HT 2A might be responsible for clozapine's cataleptic effects.</s><s>We again observed an effect of genotype (F (3, 99) ¼ 8.667, Po0.0001) and a genotype Â treatment interaction (F (3, 99) ¼ 2.998, Po0.05); however, expression of 5-HT 2A in DAT-Cre-expressing neurons did not restore clozapine's locomotor-suppressing effect (Figure <ref type="figure" target="#fig_4">5b</ref>: KO vs DAT-Cre-driven 5-HT 2A -expressing mice, P ¼ 0.1068).</s></p><p><s>Righting reflex.</s><s>Another measure of sedative behavior is the righting reflex.</s><s>We measured the righting reflex in WT, Cre controls, 5-HT 2A KO mice, and mice with 5HT 2A Figure <ref type="figure">3</ref> Clozapine, risperidone, and haloperidol reduced locomotor activity in wild-type (WT) mice (N ¼ 10 per treatment), relative to vehicletreated animals (N ¼ 9) (a).</s><s>Serotonin 2A (5-HT 2A ) knockout (KO) mice were sensitive to the locomotor suppression caused by haloperidol (N ¼ 10) and risperidone (N ¼ 10), but were resistant to the effects of clozapine (N ¼ 10) (a).</s><s>AC90179 alone was not significantly different from vehicle (b) (N ¼ 10 per group) and SB242084 increased activity in both genotypes (N ¼ 10 per group).</s><s>Co-administration resulted in a significant increase in activity in KO mice (N ¼ 13, Po0.05), while in WT mice AC90179 antagonism of the 5-HT 2A cancelled out the hyperlocomotion produced following SB242084 alone (N ¼ 9) (b).</s><s>Mice treated with haloperidol and AC90179 (N ¼ 10 per group) were significantly different from vehicle, but not from haloperidol alone (c).</s><s>Mice treated with SB242084 (N ¼ 10 per group) again displayed hyperactivity relative to vehicle-treated mice (N ¼ 11 per group) (d).</s><s>Haloperidol (N ¼ 10 WT, 12 KO) decreased distance traveled, while haloperidol plus SB242084 (N ¼ 13 WT, 9 KO) was significantly different from haloperidol alone (Po0.0001) and from SB242084 alone (Po0.0001), but not from vehicle treatment (Po0.6860)</s><s>(d).</s><s>A significant effect of genotype was seen following clozapine administration (N ¼ 12 WT, 9 KO; vehicle-treated mice, N ¼ 10 WT, 9 KO).</s><s>Significant differences were also observed following risperidone + SB242084 (N ¼ 21 WT, 22 KO) and a trend was observed following co-injection of haloperidol, AC90179, and SB242084 (N ¼ 10 WT, 11 KO) (treatment effect, P ¼ 0.071; genotype effect, EMX1-Cre: A. significant effect of treatment was observed (F (1, 50) ¼ 23.747, Po0.0001; Figure <ref type="figure" target="#fig_4">5c</ref>) with clozapine exerting a sedative effect on the mice.</s><s>This effect was not equal across all genotypes with significant genotype (F (3, 50) ¼ 5.662, Po0.01) and genotype Â treatment interaction (F (3, 50) ¼ 5.662, Po0.01) effects observed.</s><s>The interaction was caused by significant differences in response to clozapine, where 5-HT 2A KO mice were not observed to be sedated following clozapine (KO vs WT, Po0.01; KO vs Cre control, Po0.01).</s><s>Moreover, the rescue of 5HT 2A in the cortex did not restore WT-like behavior to the mice (Rescue vs WT, Po0.05; Rescue vs Cre control, Po0.05; Rescue vs KO, P ¼ 0.5698).</s></p><p><s>DAT-Cre: Expression of 5-HT 2A in nigrostriatal neurons did not restore the locomotor-suppressing effects of clozapine (Figure <ref type="figure" target="#fig_4">5d</ref>).</s><s>Again a significant effect of treatment (F (1, 99) ¼ 59.515, Po0.0001), genotype (F (3, 99) ¼ 25.126, Po0.0001), and a treatment Â genotype interaction (F (3, 99) ¼ 25.872, Po0.0001) was observed.</s><s>5-HT 2A KO mice and mice with 5-HT 2A expressed only in DAT-containing cells were significantly different to WT mice (Po0.0001 and Po0.0001, respectively) and to Cre control mice (Po0.0001 and Po0.0001, respectively).</s><s>DAT-Cre 5-HT 2A mice did not differ significantly from 5-HT 2A KO mice (P ¼ 0.5192).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>Advances in psychopharmacotherapy have seen an increase in efficacy and decreased EPS, but second-generation antipsychotics are nonetheless associated with unpleasant side effects.</s><s>Although these compounds are highly nonselective, research using animal models is helping to unravel the role of specific receptors in the beneficial effects and the adverse effects.</s><s>Recent studies demonstrate that 5-HT 2A antagonists can attenuate psychotomimetic behavioral responses, by modulating serotonergic tone <ref type="bibr" target="#b20">(Martin et al, 1998)</ref>.</s><s>That said, it has also been shown that while modulation of the serotonergic tone is necessary for the therapeutic effects of clozapine <ref type="bibr" target="#b44">(Yadav et al, 2011)</ref>, this is not dependent on either 5-HT 2A (predominantly postsynaptic) <ref type="bibr" target="#b44">(Yadav et al, 2011)</ref> or 5HT 1A (largely autoreceptors) <ref type="bibr" target="#b33">(Scorza et al, 2010)</ref>.</s><s>In this context, the central role played by 5-HT 2A in mediating the adverse effects of atypical antipsychotics acquires increased significance for future drug discovery.</s></p><p><s>The focus of this study was the behavioral response to combined D 2 , 5-HT 2A , and 5-HT 2C receptor antagonism, common to many atypical antipsychotics and several interesting findings emerge.</s><s>Primarily, we show that atypical antipsychotic-induced locomotor suppression is driven by a forebrain glutamatergic locus of activity, and that 5-HT 2A receptors mediate this effect.</s><s>The data also support the role of D 2 in mediating catalepsy in mice, and appear to preclude a role for 5-HT 2A receptors in controlling this response.</s><s>Finally, these experiments reproduce the oppositional relationship between 5-HT 2A and 5-HT 2C in their influence over locomotor behavior <ref type="bibr" target="#b11">(Halberstadt et al, 2009)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The Role Played by 5-HT2AR in Catalepsy</head><p><s>Catalepsy in rodents is considered to accurately predict EPS in humans and both behaviors are thought to result from strong antagonism at the D 2 .</s><s>Although some studies have implicated serotonin in the modulation of cataleptic behavior, reports have been mixed, and a rationale for the divergence in these findings has not been proposed.</s><s>A catalepsy-prone strain of inbred rats display decreased 5-HT 2A in the striatum in comparison to the catalepsyresistant Wistar rat strain <ref type="bibr" target="#b17">(Kulikov et al, 2002)</ref>.</s><s>Furthermore, the combined 5-HT 2A /5-HT 2C antagonist, ketanserin, has been postulated to overcome the cataleptic effects of haloperidol <ref type="bibr" target="#b6">(Creed-Carson et al, 2011)</ref>.</s><s>However, a separate study demonstrated that lower doses of a 5-HT 2A inverse agonist did not affect cataleptic behavior following either haloperidol or risperidone <ref type="bibr" target="#b8">(Gardell et al, 2007)</ref>.</s><s>Interestingly, both agonism <ref type="bibr" target="#b28">(Prinssen et al, 2002)</ref> and antagonism <ref type="bibr" target="#b40">(Wadenberg, 1996)</ref> of the 5-HT 1A have been shown to weaken catalepsy in rodents, whereas the antagonists have been shown to attenuate EPS in primates <ref type="bibr" target="#b2">(Casey, 1993)</ref>.</s><s>Consistent with published work, we show that haloperidol and high-dose risperidone cause catalepsy in rodents, driven by strong antagonism at the D 2 (seen in many first-generation neuroleptics as well as high doses of some second-generation antipsychotics, such as risperidone) <ref type="bibr" target="#b42">(Wiley and Evans, 2008)</ref>.</s><s>In support of the findings of Gardell and colleagues, in our dose-response curve we show that WT mice are no more sensitive to catalepsy than 5-HT 2A KO mice following haloperidol and risperidone.</s><s>Nonetheless, we do report some attenuation of the catalepsy response in mice treated with haloperidol in combination with both 5-HT 2A and 5-HT 2C antagonists, whereas neither of these compounds affected haloperidol-induced catalepsy on their own.</s><s>Taken together, our findings, and those reported previously, suggest that substantial changes in serotonergic signaling through multiple receptors are required to overcome the catalepsy caused by D 2 antagonism following typical antipsychotic administration.</s><s>This may be achieved either by targeting the presynaptic 5-HT 1A , controlling 5-HT release and thus the postsynaptic response, or by directly blocking both postsynaptic 5-HT 2 receptors.</s><s>This supports the notion that the primary and most crucial mechanism underlying neuroleptic-induced catalepsy is via the indirect striatopallidal output pathway, driven by D 2 blockade.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serotonergic Control of Locomotor Activation and Suppression</head><p><s>Locomotor suppression induced by clozapine in rodents is widely acknowledged; however, there has been a paucity of research invested in addressing the mechanism by which this is achieved.</s><s>The results herein provide critical insight into how these behaviors occur; however, the unexpected nature of the findings also open up several important avenues for further investigation.</s><s>How does 5-HT 2A regulate these behaviors?</s><s>Which second messenger systems control this response?</s><s>Can we dissociate these pathways from those that control therapeutic efficacy?</s></p><p><s>Inverse agonism of 5-HT 2A and 5-HT 2C (with AC90179 and SB242084 respectively), administered in combination with haloperidol, resulted in reduced locomotor activity, similar to that observed following atypical antipsychotics.</s><s>Although it is not possible to definitively relate the atypical antipsychotic-induced locomotor suppression directly to a human correlate, it is tempting to speculate that the decreased activity in mice may be analogous to the sedative effects of atypical antipsychotics in schizophrenia patients.</s><s>Muscarinic M 1 receptors, histaminergic H 1 receptors, and a1 adrenergic receptors <ref type="bibr" target="#b4">(Cooper, 1986;</ref><ref type="bibr" target="#b26">Nicholson, 1983;</ref><ref type="bibr" target="#b30">Sallinen et al, 2007)</ref> have been associated with wakefulness and their respective neurotransmitters are known to be involved in the arousal pathways <ref type="bibr" target="#b3">(Castberg et al, 2006;</ref><ref type="bibr" target="#b36">Stahl, 2008;</ref><ref type="bibr" target="#b37">Stahl and Shayegan, 2003)</ref>.</s><s>As such, the belief has been that these receptors and their downstream signaling systems are likely to be responsible for atypical antipsychotic-induced sedation, which has a significant impact on the quality of life of schizophrenia patients (Asenjo <ref type="bibr" target="#b0">Lobos et al, 2010)</ref>.</s><s>In addition, previous reports have shown that blocking dopamine D 2 can cause locomotor suppression and neurolepsis at high doses <ref type="bibr" target="#b13">(Huang et al, 2010;</ref><ref type="bibr">Shireen and Haleem, Starr and Starr, 1987)</ref>; however, this is likely associated with the cataleptic nature of D 2 antagonism.</s></p><p><s>Here, we show that 5-HT 2A receptors are required to produce this phenotype.</s><s>To our knowledge, 5-HT 2A has not previously been considered as a target for this behavior.</s><s>As such, it is important to note that 5-HT 2A have been shown to influence H 1 and M 1 signaling <ref type="bibr" target="#b12">(Hirano et al, 1995;</ref><ref type="bibr" target="#b25">Morisset et al, 1999)</ref>.</s><s>However, although we cannot rule it out altogether, our results are indicative of a locomotor suppression that is independent of histaminergic or muscarinic tone, as we do not observe a differential response to diphenhydramine, a histamine receptor antagonist, nor to scopolamine, a muscarinic antagonist, in the 5-HT 2A knockout mice, relative to WT mice.</s></p><p><s>Interestingly, while WT mice display a dose-dependent decrease in locomotor behavior in response to clozapine, 5-HT 2A KO mice display a muted, U-shaped, locomotor response curve, which may be attributable to the yin-yang relationship between 5-HT 2A and 5-HT 2C .</s><s>The data show that antagonism of 5-HT 2C produces robust locomotor activation that can be attenuated by antagonism of the 5-HT 2A receptor, findings that complement previously published research demonstrating that agonism at the 5-HT 2A increases activity in a manner which can be countered by 5-HT 2C agonism <ref type="bibr" target="#b11">(Halberstadt et al, 2009)</ref>.</s><s>With increasing doses of clozapine one would produce increasing antagonism at the 5HT 2C , resulting in locomotor activation in the absence of 5-HT 2A receptors.</s></p><p><s>We also observed a divergence in the population of 5-HT 2A responsible for locomotor suppression vs the righting reflex, which may be attributed to subtle differences in the behaviors being tested, the level of motivation required to perform the task, and the underlying neural circuits.</s><s>In fact, while we demonstrate the importance of cortical 5-HT 2A in mediating locomotor suppression, it is generally believed that the righting reflex is predominantly a cerebellar behavior <ref type="bibr" target="#b14">(Johnson et al, 1985;</ref><ref type="bibr" target="#b35">Spuhler et al, 1982;</ref><ref type="bibr" target="#b39">Tanaka and Okeda, 2000)</ref>.</s></p><p><s>Another interesting finding, which may provide some clue as to the underlying mechanism, is the distinction between the effects of chronic absence of the 5-HT 2A and the effect of acute antagonism of this receptor.</s><s>Specifically, that clozapine (a 5-HT 2A antagonist) is dependent on the presence of the 5-HT 2A , but not 5-HT 2C , for its locomotorsuppressing effects is seemingly counter-intuitive.</s><s>In this context, it is important to consider how the constitutive absence of 5-HT 2A might impact upon neural development, and adult neurochemistry and neuroanatomy.</s><s>To date, we have not identified any significant compensatory changes caused by the constitutive absence of 5HT 2A that could explain the observed genotype difference <ref type="bibr" target="#b41">(Weisstaub et al, 2006)</ref>.</s><s>That said, more thorough investigations may reveal additional changes in other signaling pathway components.</s><s>One such possibility would be changes in expression of the immediate early gene (IEG), Egr3.</s><s>The potential importance of Egr3 in mediating this behavior, and its possible link to the 5-HT 2A receptor, is presented in detail in a recent publication and we will thus refrain from further elaboration on the relevance of this point <ref type="bibr" target="#b43">(Williams et al, 2012;</ref><ref type="bibr" target="#b7">Gallitano-Mendel et al, 2008)</ref>.</s><s>However, should this signaling pathway be found to modulate 5-HT 2A activity, it would provide a parsimonious explanation for the divergence between the effect of the receptor knockout and the pharmacological inactivation of the receptor.</s><s>Moreover, it would be consistent with the decreased expression of 5-HT 2A observed in the egr3 KO mice.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>To date, the neurochemical and neuroanatomical loci underlying many of the side effects associated with clozapine have not been widely explored and academic discourse and drug discovery have moved forward in the absence of this important information.</s><s>This series of experiments are among the first to identify categorically a neural locus for the locomotor suppression induced by clozapine, while at the same time identifying a novel target for the neurochemical pathways involved (see also <ref type="bibr" target="#b43">Williams et al, 2012)</ref>.</s><s>The regulation of clozapine-induced locomotor suppression by glutamatergic forebrain 5-HT 2A -expressing neurons provides insight into the adverse effects of antipsychotics, clarifying our understanding of the neural circuitry underlying the side effects induced by antipsychotics.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure1Mice were treated with antipsychotic drugs across a range of doses and locomotor activity in the open field was assessed for 30 min.</s><s>Haloperidol, at doses of 0.1 mg/kg and higher, significantly decreased locomotor activity in both wild-type (WT) and serotonin 2A (5-HT 2A ) knockout (KO) mice (a: untreated, N ¼ 26 WT, 34 KO; haloperidol treated, N ¼ 11 KO, 9 WT).</s><s>Risperidone at both low and high doses also decreased activity comparably in both WT and KO mice (b: untreated, N ¼ 26 WT, 34 KO; haloperidol treated, N ¼ 11 KO, 9 WT).</s><s>Clozapine treatment resulted in extreme sedation in WT mice from 5 mk/kg upwards (c: untreated, N ¼ 26 WT, 34 KO; haloperidol treated, N ¼ 12 KO, 8 WT).</s><s>In KO mice, clozapine did not induce this extreme level of sedation until 30 mg/kg.</s><s>Data are shown as mean±SEM.</s><s># Po0.05 difference from WT.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure2Haloperidol and risperidone caused catalepsy in both wild-type (WT) (N ¼ 19-33) and knockout (KO) mice (N ¼ 21-31) in a dosedependent manner (a).</s><s>At doses of 0.4 mg/kg haloperidol and risperidone both induced catalepsy relative to vehicle-treated mice.</s><s>Clozapine 5 mg/kg (N ¼ 22 WT, 19 KO), however, did not induce catalepsy in either genotype (b).</s><s>The serotonin 2A (5-HT 2A ) antagonist AC90179 (c) (N ¼ 21 WT, 23 KO) and the 5-HT 2C antagonist SB242084 (d) (N ¼ 34 WT, 30 KO) alone did not affect catalepsy nor did they alter the cataleptic response to haloperidol (N ¼ 9-13).</s><s>Mice treated with risperidone and SB242084 (N ¼ 11 WT, 10 KO) showed significantly less catalepsy than haloperidoltreated mice (e: N ¼ 10 WT, 12 KO).</s><s>They were also significantly different to mice treated with vehicle (N ¼ 10 WT, 9 KO) (e).</s><s>Co-administration of SB242084 and AC90179 with haloperidol (N ¼ 10 WT, 11 KO) also attenuated catalepsy.</s><s>However, catalepsy levels were still significantly higher than vehicle-treated mice (N ¼ 10 WT, 9 KO) (e).</s><s>Data are shown as mean ± SEM. ***Po0.0001</s><s>difference from vehicle treatment.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>Figure3Clozapine, risperidone, and haloperidol reduced locomotor activity in wild-type (WT) mice (N ¼ 10 per treatment), relative to vehicletreated animals (N ¼ 9) (a).</s><s>Serotonin 2A (5-HT 2A ) knockout (KO) mice were sensitive to the locomotor suppression caused by haloperidol (N ¼ 10) and risperidone (N ¼ 10), but were resistant to the effects of clozapine (N ¼ 10) (a).</s><s>AC90179 alone was not significantly different from vehicle (b) (N ¼ 10 per group) and SB242084 increased activity in both genotypes (N ¼ 10 per group).</s><s>Co-administration resulted in a significant increase in activity in KO mice (N ¼ 13, Po0.05), while in WT mice AC90179 antagonism of the 5-HT 2A cancelled out the hyperlocomotion produced following SB242084 alone (N ¼ 9) (b).</s><s>Mice treated with haloperidol and AC90179 (N ¼ 10 per group) were significantly different from vehicle, but not from haloperidol alone (c).</s><s>Mice treated with SB242084 (N ¼ 10 per group) again displayed hyperactivity relative to vehicle-treated mice (N ¼ 11 per group) (d).</s><s>Haloperidol (N ¼ 10 WT, 12 KO) decreased distance traveled, while haloperidol plus SB242084 (N ¼ 13 WT, 9 KO) was significantly different from haloperidol alone (Po0.0001) and from SB242084 alone (Po0.0001), but not from vehicle treatment (Po0.6860)</s><s>(d).</s><s>A significant effect of genotype was seen following clozapine administration (N ¼ 12 WT, 9 KO; vehicle-treated mice, N ¼ 10 WT, 9 KO).</s><s>Significant differences were also observed following risperidone + SB242084 (N ¼ 21 WT, 22 KO) and a trend was observed following co-injection of haloperidol, AC90179, and SB242084 (N ¼ 10 WT, 11 KO) (treatment effect, P ¼ 0.071; genotype effect, Po0.1085) (e).</s><s>Data are shown as mean±SEM.</s><s>*Po0.05,</s><s>**Po0.01,</s><s>***Po0.0001</s><s>difference from vehicle treatment.</s><s># Po0.05, ### Po0.0001 indicates a significant difference in behavior of the KO relative to WT mice under the same treatment regimen.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4</head><label>4</label><figDesc><div><p><s>Figure4Wild-type (WT) mice and serotonin 2C (5-HT 2C ) knockout (KO) mice showed comparable levels of baseline locomotion and were equally affected by clozapine treatment of 5 mg/kg (a).</s><s>In 5-HT 2A KO mice, olanzapine produces a similar effect to that observed following clozapine, with WT mice demonstrating reduced locomotor behavior relative to saline-treated animals, while 5HT 2A KO mice are resistant to this effect (b).</s><s>Scopolamine (c) and diphenhydramine (d) both produced an increase in locomotion that was not dependent on 5-HT 2A receptor signaling.</s><s>Data are shown as mean ± SEM. **Po0.01,</s><s>***Po0.0001</s><s>difference from vehicle treatment.</s><s>### Po0.0001 indicates a significant difference in behavior of the KO relative to WT mice under the same treatment regimen.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 5</head><label>5</label><figDesc><div><p><s>Figure 5 As found previously, clozapine dramatically reduced locomotor activity in wild-type (WT) mice (a) (N ¼ 7) as well as in Cre control mice (N ¼ 8).</s><s>The locomotor behavior of serotonin 2A (5-HT 2A ) knockout (KO) mice was unaffected by clozapine treatment (N ¼ 7); however, mice expressing htr2ar in the cortex (N ¼ 7 saline, 8 clozapine treated) behaved like WT mice, showing decreased locomotor activity following clozapine treatment.</s><s>(b) At baseline, 5-HT 2A -DAT-Cre rescue mice showed slightly elevated baseline activity.</s><s>Clozapine attenuated this locomotion in WT and DAT-Cre control mice; however, it did not affect the activity of KO (n ¼ 11) or 5HT 2A -DAT mice (N ¼ 15).</s><s>(c) Clozapine impaired the righting reflex in WT mice (N ¼ 7) and EMX1-Cre control mice (N ¼ 8).</s><s>Righting reflex was not impaired in KO mice following clozapine (N ¼ 7) nor was it impaired in 5-HT 2A -EMX1-Cre mice (N ¼ 7).</s><s>(d) In a subsequent cohort of mice, we again observed impaired righting reflex in WT (n ¼ 15) and DAT-Cre control mice (N ¼ 12).</s><s>KO mice were resistant to this response (N ¼ 11) as were 5-HT 2A -DAT-Cre rescue mice (N ¼ 15).</s><s>No significant genotype effects were observed in saline-treated mice as none of the groups displayed impaired righting reflex (data not shown).</s><s>Data are shown as mean±SEM.</s><s>**Po0.01,</s><s>***Po0.0001</s><s>difference from vehicle treatment.</s><s># Po0.05, ## Po0.01, ### Po0.0001 indicates a significant difference in behavior of the KO relative to WT mice under the same treatment regimen.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>: effect of genotype, F (1, 243) ¼ 1.108, P ¼ 0.2935; effect of treatment, F (3, 243) ¼ 116.673,</s><s>Po0.0001; AC90179 vs vehicle, P ¼ 0.2082) or SB242084 (Figure 2d: effect of genotype, F (1, 265) ¼ 0.101, P ¼ 0.7509; effect of treatment, F (3, 265) ¼ 124.749,</s><s>Po0.0001; SB242084 vs vehicle, P ¼ 0.2126).</s><s>Interestingly, while 'risperidone with SB242084' and 'haloperidol with AC90179 and SB242084' both induced significant catalepsy relative to vehicletreated mice (Figure 2e: effect of genotype, F (1, 243) ¼ 0.2224, P ¼ 0.2224; effect of treatment, F (3, 243) ¼ 66.491, Po0.0001; risperidone + SB242084 vs vehicle, Po0.0001; haloperidol + AC90179 + SB242084 vs vehicle, Po0.0001), they were nonetheless significantly less cataleptic than haloperidol alone (risperidone + SB242084 vs haloperidol, Po0.0001; haloperidol + AC90179 + SB242084 vs haloperidol, Po0.0001).</s></p></div></figDesc><table /></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>ACKNOWLEDGEMENTS</head><p>We acknowledge <rs type="funder">Acadia Pharmaceuticals</rs> for the generous gift of the AC90179.We would also like to acknowledge funding from the <rs type="funder">NH&amp;MRC (CEM)</rs>, <rs type="funder">NIMH</rs>, <rs type="funder">NIDA</rs> (<rs type="grantNumber">5 PO1 DA012923-08</rs>), Lieber Center for Schizophrenia Research, and the <rs type="institution">Sackler Institute (JAG)</rs>.We thank <rs type="person">Elena Demireva</rs>, <rs type="person">Elizabeth LaMarca</rs>, and <rs type="person">Maria Milekic</rs> for their vital input to the manuscript.</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_aN33awG">
					<idno type="grant-number">5 PO1 DA012923-08</idno>
				</org>
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCLOSURE</head><p><s>The authors declare no conflict of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Clozapine vs other atypical antipsychotics for schizophrenia</title>
		<author>
			<persName><forename type="first">Asenjo</forename><surname>Lobos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Komossa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rummel-Kluge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hunger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<idno>CD006633</idno>
	</analytic>
	<monogr>
		<title level="s">Cochrane Database Syst Rev</title>
		<imprint>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Beninger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Florczynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Banasikowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurotox Res</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="229" to="243" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Casey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="55" to="S59" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Adverse drug reactions of antidepressants and antipsychotics: experience, knowledge and attitudes among Norwegian psychiatrists</title>
		<author>
			<persName><forename type="first">I</forename><surname>Castberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Reimers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sandvik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">O</forename><surname>Aamo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Spigset</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nord J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="227" to="233" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">H-1 blockersFclassical antihistamines</title>
		<author>
			<persName><forename type="first">Cooper</forename><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl Reg Allergy Proc</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="356" to="361" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">General pharmacology of clozapine</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Coward</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Psychiatry Suppl</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="5" to="11" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats</title>
		<author>
			<persName><forename type="first">M</forename><surname>Creed-Carson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oraha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Nobrega</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behav Brain Res</title>
		<imprint>
			<biblScope unit="volume">219</biblScope>
			<biblScope unit="page" from="273" to="279" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Mice lacking the immediate early gene respond to the anti-aggressive effects of clozapine yet are relatively resistant to its sedating effects</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gallitano-Mendel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Wozniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Pehek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Milbrandt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1266" to="1275" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Gardell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Vanover</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pounds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Barido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">322</biblScope>
			<biblScope unit="page" from="862" to="870" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gorski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Talley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Puelles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Rubenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Jones</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="6309" to="6314" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Specificity and efficiency of Cre-mediated recombination in Emx1-Cre knock-in mice</title>
		<author>
			<persName><forename type="first">H</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">L</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Avasthi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Tu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="volume">273</biblScope>
			<biblScope unit="page" from="661" to="665" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Halberstadt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Van Der Heijden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Ruderman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">B</forename><surname>Risbrough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gingrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Geyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1958" to="1967" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Serotonergic regulation of acetylcholine release in rat frontal cortex</title>
		<author>
			<persName><forename type="first">H</forename><surname>Hirano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Fibiger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="1139" to="1145" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Dose-dependent dissociable effects of haloperidol on locomotion, appetitive responses, and consummatory behavior in water-deprived rats</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Shyu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hsiao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Biochem Behav</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="285" to="291" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Correlation of Purkinje neuron depression and hypnotic effects of ethanol in inbred strains of rats</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Hoffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Freedman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Alcohol Clin Exp Res</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="56" to="58" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">O</forename><surname>Kalkman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Neumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hoyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Tricklebank</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="1550" to="1556" />
			<date type="published" when="1998">1998a</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">O</forename><surname>Kalkman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Neumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Nozulak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Tricklebank</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="page" from="201" to="207" />
			<date type="published" when="1998">1998b</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Effect of chronic thyroxine treatment on catalepsy in rats</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Kulikov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">N</forename><surname>Barykina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Tikhonova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">F</forename><surname>Chuguy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">G</forename><surname>Kolpakov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Popova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">330</biblScope>
			<biblScope unit="page" from="207" to="209" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Second-generation vs first-generation antipsychotic drugs for schizophrenia: a meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Leucht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Corves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Arbter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="31" to="41" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Lieberman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Stroup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Mcevoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Swartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Rosenheck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">O</forename><surname>Perkins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="1209" to="1223" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone</title>
		<author>
			<persName><forename type="first">P</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Waters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Carlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Carlsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neural Transm</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="365" to="396" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Mccormick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kapur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Graff-Guerrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Raymond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Nobrega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Wilson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1826" to="1835" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Effectiveness of clozapine vs olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Mcevoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Lieberman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Stroup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Meltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Rosenheck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="page" from="600" to="610" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The role of serotonin receptors in the action of atypical antipsychotic drugs</title>
		<author>
			<persName><forename type="first">H</forename><surname>Meltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Massey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="59" to="67" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Clozapine-induced weight gain predicts improvement in psychopathology</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Meltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jayathilake</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="19" to="27" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Atypical neuroleptics enhance histamine turnover in brain via 5-hydroxytryptamine2A receptor blockade</title>
		<author>
			<persName><forename type="first">S</forename><surname>Morisset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">G</forename><surname>Sahm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Traiffort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tardivel-Lacombe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Arrang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Schwartz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">288</biblScope>
			<biblScope unit="page" from="590" to="596" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Antihistamines and sedation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Nicholson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="211" to="212" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Parada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Puig</forename><surname>De Parada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Murzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">281</biblScope>
			<biblScope unit="page" from="582" to="588" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Prinssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Colpaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Koek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">453</biblScope>
			<biblScope unit="page" from="217" to="221" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Magic shotguns vs magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Sheffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Kroeze</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Drug Discov</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="353" to="359" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sallinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Hoglund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Engstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lehtimaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Virtanen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sirvio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="391" to="402" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding</title>
		<author>
			<persName><forename type="first">A</forename><surname>Schotte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Janssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Gommeren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Luyten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Gompel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Lesage</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology (Berl)</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="57" to="73" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography</title>
		<author>
			<persName><forename type="first">A</forename><surname>Schotte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Janssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Megens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Leysen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Res</title>
		<imprint>
			<biblScope unit="volume">631</biblScope>
			<biblScope unit="page" from="191" to="202" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Scorza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Castane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bortolozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Artigas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="112" to="120" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats</title>
		<author>
			<persName><forename type="first">E</forename><surname>Shireen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Haleem</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pak J Pharm Sci</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="7" to="12" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Evidence for genetic correlation of hypnotic effects and cerebellar Purkinje neuron depression in response to ethanol in mice</title>
		<author>
			<persName><forename type="first">K</forename><surname>Spuhler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hoffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Weiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Palmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Biochem Behav</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="569" to="578" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<monogr>
		<title level="m" type="main">Antipsychotics and Mood Stabilizers 3rd edn</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Stahl</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
			<publisher>Cambridge University Press</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Stahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Shayegan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="6" to="12" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Suppl 19</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Behavioural interactions involving D1 and D2 dopamine receptors in non-habituated mice</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Starr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Starr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="613" to="619" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">N-[4-(3-ethoxy-2-hydropropoxy)phenyl] acrylamide selectively induces apoptosis of cerebellar granule cells in vivo and in vitro in rats</title>
		<author>
			<persName><forename type="first">G</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Okeda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="337" to="344" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Serotonergic mechanisms in neurolepticinduced catalepsy in the rat</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Wadenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Biobehav Rev</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="325" to="339" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Weisstaub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lambe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gonzalez-Maeso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Hornung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">313</biblScope>
			<biblScope unit="page" from="536" to="540" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Evaluation of age and sex differences in locomotion and catalepsy during repeated administration of haloperidol and clozapine in adolescent and adult rats</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Wiley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Evans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Res</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="240" to="246" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Reduced levels of serotonin 2A receptors underline resistance of Egr 3 deficient mice to locomotor suppression by clozapine</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Ingram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Resnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Kamel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Lish</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<date type="published" when="2012-06">2012. June 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">The presynaptic component of the serotonergic system is required for clozapine&apos;s efficacy</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Yadav</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Abbas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Farrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Setola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sciaky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">P</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="638" to="651" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Targeted gene expression in dopamine and serotonin neurons of the mouse brain</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Masson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gingrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rayport</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci Methods</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="27" to="32" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
